Sectors
TVTX
Travere Therapeutics, Inc.
55.69
1 x 55.65
1 x 55.71
bid
ask
-
0.89
1.57%
01:09 PM
timesize
| Ytd | 45.74% | |
| 1y | 255.61% |
55.29
day range
56.16
15.03
52 week range
60.10
| Open | 55.29 | Prev Close | 56.58 | Low | 55.29 | High | 56.16 | Mkt Cap | 5.26B |
| Vol | 309.53K | Avg Vol | 2.12M | EPS | -0.22 | P/E | -257.18 | Forward P/E | 77.52 |
| Beta | 1.10 | Short Ratio | 5.25 | Inst. Own | 113.77% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-04 | 50-d Avg | 50.96 | 200-d Avg | 37.12 | 1yr Est | 58.36 |
| Income Statement | |||
| Total Revenue | 127.20M | ||
| Revenues (USD) | 127.20M | ||
| Cost of Revenue | 1.95M | ||
| Gross Profit | 125.25M | ||
| Operating Expenses | 162.16M | ||
| Research and Development Expense | 57.09M | ||
| Selling, General and Administrative Expense | 80.25M | ||
| Operating Income | -36.91M | ||
| Interest Expense | 2.30M | ||
| Income Tax Expense | -120.00K | ||
| Net Income | -37.10M | ||
| Net Income Common Stock | -37.10M | ||
| Net Income Common Stock (USD) | -37.10M | ||
| Consolidated Income | -37.10M | ||
| Net Income from Discontinued Operations | 500.00K | ||
| Earnings per Basic Share | -0.40 | ||
| Earnings per Basic Share (USD) | -0.40 | ||
| Earnings per Diluted Share | -0.40 | ||
| Earning Before Interest & Taxes (EBIT) | -34.92M | ||
| Earning Before Interest & Taxes (USD) | -34.92M | ||
| Weighted Average Shares | 91.87M | ||
| Weighted Average Shares Diluted | 91.87M | ||
| Balance Sheet | |||
| Cash and Equivalents | 78.36M | ||
| Cash and Equivalents (USD) | 78.36M | ||
| Investments | 186.31M | ||
| Investments Current | 186.31M | ||
| Trade and Non-Trade Receivables | 87.30M | ||
| Current Assets | 392.68M | ||
| Property, Plant & Equipment Net | 13.30M | ||
| Total Assets | 555.19M | ||
| Debt Current | 6.02M | ||
| Total Debt | 327.66M | ||
| Current Liabilities | 125.44M | ||
| Debt Non-Current | 321.65M | ||
| Total Liabilities | 456.46M | ||
| Accumulated Retained Earnings (Deficit) | -1.51B | ||
| Accumulated Other Comprehensive Income | -1.06M | ||
| Shareholders Equity | 98.73M | ||
| Shareholders Equity (USD) | 98.73M | ||
| Assets Non-Current | 162.51M | ||
| Total Debt (USD) | 327.66M | ||
| Goodwill and Intangible Assets | 110.04M | ||
| Inventory | 37.05M | ||
| Liabilities Non-Current | 331.02M | ||
| Trade and Non-Trade Payables | 12.91M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 25.21M | ||
| Net Cash Flow from Financing | 4.20M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -14.67M | ||
| Capital Expenditure | -22.18M | ||
| Issuance (Purchase) of Equity Shares | 4.73M | ||
| Net Cash Flow from Investing | 21.55M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 43.73M | ||
| Net Cash Flow from Operations | -40.37M | ||
| Effect of Exchange Rate Changes on Cash | -60.00K | ||
| Share Based Compensation | 16.15M | ||